Physician profile
Aman Saw
NPI 1184865982
$5,112.97
in general payments reported to CMS, 2019-2025
32 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $169 · 2021: $378 · 2022: $724 · 2023: $1,228 · 2024: $1,813 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,339.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,597.40 | 2019-2025 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply |
| Novartis Pharmaceuticals Corporation | $491.94 | 2019-2025 | |
| Biotronik INC. | $351.82 | 2020-2024 | Orsiro Mission, Amvia Edge, Biomonitor |
| Amgen INC. | $326.06 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.80 | 2023-2024 | Lifevest |
| Abiomed | $256.40 | 2021-2023 | Impella |
| Philips North America LLC | $240.72 | 2019-2025 | Extended Holter |
| Janssen Pharmaceuticals, INC | $206.91 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $204.08 | 2022-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.58 | 2023-2024 | Jardiance |
| Irhythm Technologies, INC. | $114.09 | 2022-2024 | Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $86.16 | 2024 | Arcalyst |
| Cordis US Corp. | $85.83 | 2022 | |
| Merck Sharp & Dohme LLC | $75.51 | 2022-2023 | Verquvo |
| Impulse Dynamics (USA) INC. | $60.76 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58.16 | 2024 | Amplatzer Amulet, Assurity |
| Medtronic, INC. | $51.25 | 2025 | Venaseal |
| Lexicon Pharmaceuticals, INC. | $47.90 | 2024 | |
| Kestra Medical Technology Services, INC. | $45.12 | 2022 | |
| Pfizer INC. | $44.39 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $43.20 | 2023 | Arcalyst |
| Terumo Medical Corporation | $36.56 | 2024 | Metacross Otw |
| Atricure, INC. | $32.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.78 | 2025 | |
| Heartflow, INC. | $27.22 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $23.80 | 2023 | Eliquis |
| Cardiovascular Systems INC. | $22.95 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.71 | 2023 | Xifaxan |
| Novo Nordisk INC | $22.50 | 2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $22.10 | 2022 | |
| Genentech USA, INC. | $15.47 | 2019 | |
| Shockwave Medical, INC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Saw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.